Site Editor
Jeremy S. Abramson, MD, MMSc
Jeremy S. Abramson, MD, MMSc
Posted: Monday, March 10, 2025
Metabolic response at the end of treatment and baseline metabolic tumor burden parameters—metabolic tumor volume and total lesion glycosis—appear to be the strongest predictors of progression-free survival in patients with advanced mantle cell lymphoma (MCL), according to the results of a single-center, 120-patient retrospective study published in Hematological Oncology. The research investigated the prognostic role of tumor burden and tumor dissemination features derived by fluorine-18–fluorodeoxyglucose PET/CT (2-[18F]FDG PET/CT), explained Domenico Albano, MD, of Università degli Studi di Brescia, Italy, and colleagues.
Dissemination features, corrected for body surface area, may have a significant role in predicting overall survival, the authors continued. All patients (75% male; mean age, 65.6 years) underwent baseline 2-[18F]FDG PET/CT and end-of-treatment PET/CT; they were treated between 2007 and 2023.
The baseline PET images were analyzed visually and semiquantitatively. Measured were the maximum standardized uptake value (SUV) body weight, SUV lean body mass, SUV body surface area, metabolic tumor volume, total lesion glycolysis, and dissemination features (maximum tumor dissemination and maximum tumor dissemination–body surface area).
At a median follow-up of 59 months, relapse or disease progression had occurred in 68 patients, and 38 patients had died. For all patients, the median progression-free survival and overall survival were 27.2 and 57.6 months, respectively. MCL International Prognostic Index score, bulky disease, and Ki67 index were significantly associated with progression-free survival at univariate analysis, but they were not confirmed as independent prognostic factors.
In mantle cell lymphoma, said the authors, there was a high 2-[18F]FDG PET/CT detection rate regarding nodal disease, but “the diagnostic performances of PET/CT in the detection of gastrointestinal involvement and bone marrow infiltration [were] less good.” Therefore, they suggest performing “bone marrow biopsy and gastrointestinal endoscopy in the staging phase to classify correctly classify these patients.”
Disclosure: The study authors reported no conflicts of interest.
JNCCN Spotlights
